CLVS.Q Aperçu des actions
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 0/6 |
| Dividendes | 0/6 |
Clovis Oncology, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$0.015 |
| Plus haut sur 52 semaines | US$2.87 |
| Plus bas sur 52 semaines | US$0.01 |
| Bêta | 0.66 |
| 1Variation sur 1 mois | -40.00% |
| Variation sur 3 mois | -28.57% |
| Variation sur 1 an | -99.39% |
| 3Variation sur 3 ans | -99.77% |
| Variation sur 5 ans | -99.97% |
| Évolution depuis l'introduction en bourse | -99.88% |
Nouvelles et mises à jour récentes
Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10
Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05Rendement pour les actionnaires
| CLVS.Q | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 18.1% | -1.3% | -1.6% |
| 1Y | -99.4% | 19.1% | 30.1% |
Rendement vs Industrie: CLVS.Q a sous-performé le secteur US Biotechs qui a rapporté 19.1 % au cours de l'année écoulée.
Rendement vs marché: CLVS.Q a sous-performé le marché US qui a rapporté 30.1 % au cours de l'année écoulée.
Volatilité des prix
| CLVS.Q volatility | |
|---|---|
| CLVS.Q Average Weekly Movement | 61.3% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.0% |
Cours de l'action stable: Le cours de l'action de CLVS.Q a été volatil au cours des 3 derniers mois.
Volatilité au fil du temps: La volatilité hebdomadaire de CLVS.Q est passée de 39% à 61% au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2009 | 413 | Patrick Mahaffy | www.clovisoncology.com |
Clovis Oncology, Inc. Résumé des fondamentaux
| CLVS.Q statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$2.18m |
| Bénéfices(TTM) | -US$251.91m |
| Recettes(TTM) | US$133.02m |
0.0x
Ratio P/S0.0x
Ratio P/ELe site CLVS.Q est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CLVS.Q compte de résultat (TTM) | |
|---|---|
| Recettes | US$133.02m |
| Coût des recettes | US$31.59m |
| Marge brute | US$101.43m |
| Autres dépenses | US$353.33m |
| Les revenus | -US$251.91m |
Derniers bénéfices déclarés
Sep 30, 2022
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -1.73 |
| Marge brute | 76.25% |
| Marge bénéficiaire nette | -189.37% |
| Ratio dettes/capitaux propres | -158.0% |
Quelles ont été les performances à long terme de CLVS.Q?
Voir les performances historiques et les comparaisons